Description
Imfinzi 120 mg contains Durvalumab, a human monoclonal antibody that targets the programmed death-ligand 1 (PD-L1) protein. It is administered via intravenous infusion and is widely used in modern cancer immunotherapy.
🔬 Mechanism of Action
Durvalumab binds to PD-L1 and blocks its interaction with PD-1 and CD80 receptors on T-cells. As a result, it:
- Restores T-cell activity
- Enhances immune system response against cancer cells
- Promotes tumor cell destruction
This immune checkpoint inhibition allows the body to recognize and attack cancer more effectively.
💊 Indications
Imfinzi 120 mg is indicated for:
- Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) after chemoradiation
- Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (in combination with chemotherapy)
- Biliary Tract Cancer (in combination therapy as per guidelines)
📌 Key Features
- Strength: 120 mg
- Dosage Form: Intravenous infusion
- Therapeutic Class: PD-L1 Immune Checkpoint Inhibitor
- Administration: IV infusion in hospital or oncology clinic
- Monitoring: Liver, kidney, thyroid function, and immune-related adverse events monitoring required
⚕️ Benefits
- Immunotherapy-based cancer treatment
- Improves progression-free and overall survival
- Long-lasting immune response
- Effective across multiple cancer types
⚠️ Precautions
- Risk of immune-related adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies)
- Infusion-related reactions may occur
- Requires close monitoring during therapy
- Use strictly under oncologist supervision
Imfinzi 120 mg (Durvalumab Injection) is an advanced immunotherapy that enhances the body’s natural defenses to fight cancer, offering improved survival outcomes in lung and other cancers when used under specialized medical care.
